Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.
Company Overview
Exelixis Inc (EXEL) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative small molecule therapies that target various forms of cancer. As a major contributor in the oncology sector, it leverages its deep expertise in drug development to address complex unmet medical needs. The company has established a robust development platform that enables the transformation of scientific innovation into effective therapeutic solutions.
Core Business and Therapy Portfolio
Exelixis focuses primarily on oncology, offering therapies that are designed to improve the care and outcomes of patients with different types of cancer. Its flagship molecules have been developed across multiple cancer indications such as metastatic medullary thyroid cancer, kidney cancer, and liver cancer. The dual branding of its key product into distinct therapies illustrates the company’s strategy to address diverse clinical requirements. Additionally, its collaboration with a global pharmaceutical partner further highlights the company's role in bringing combination therapies to market, particularly in the treatment of melanoma.
Strategic Collaborations and Development Platform
The company has built a multifaceted clinical research framework that integrates both internal research and strategic external alliances. Key partnerships, including one with a leading pharmaceutical company and more recent collaborative efforts with Sairopa, augment its clinical development capabilities. For instance, the alliance with Sairopa has facilitated research into innovative cancer immunotherapies, such as the development of an anti-SIRPα antibody. This collaboration underscores Exelixis’ commitment to leveraging cutting-edge science to develop next-generation therapies that potentially modulate the immune system's response to cancer.
Market Position and Business Model
Exelixis positions itself as a specialized player within the oncology space, where its core business model revolves around the commercialization of small molecule therapies through both direct sales and strategic licensing agreements. The firm has demonstrated sustained expertise in navigating regulatory landscapes and establishing commercially viable products. Its business model is characterized by verified clinical success, a broad research pipeline, and a strategic focus on partnerships that enhance its ability to innovate and deliver impactful cancer treatments.
Clinical Development and Commercialization Strategy
The company’s clinical development strategy combines rigorous research protocols with smart partnerships to accelerate product development. By engaging in early-phase clinical assessments and phase-transition collaborations, Exelixis ensures that its portfolio remains robust and diversified. Its emphasis on large-scale commercialization is supported by established regulatory approvals and a comprehensive understanding of the market dynamics in oncology. Investors and market observers note the company’s careful balance between research innovation and commercial execution, which is integral to its sustained market relevance.
Industry Impact and Expertise
Exelixis has made a significant impact on the biopharmaceutical industry by focusing on high-impact areas of cancer treatment. Its expertise in small molecule design and targeted therapy development has set industry benchmarks. The company’s operations exemplify the integration of advanced scientific research with practical clinical applications, providing a model for translational medicine in oncology. With a commitment to continuous improvement and adherence to rigorous research standards, Exelixis remains a trusted name among healthcare professionals, researchers, and industry analysts.
Key Highlights
- Innovative Research: Extensive clinical development in small molecule therapies for cancer.
- Strategic Alignments: Collaborations with major pharmaceutical companies and clinical-stage developers enhance its research footprint.
- Regulatory Acumen: Proven ability to navigate regulatory requirements for global market approval.
- Diverse Portfolio: A broad range of therapies addressing multiple cancer types.
Conclusion
With a solid foundation in advanced oncology research and a dynamic strategy that integrates innovative clinical practices and strategic partnerships, Exelixis Inc exemplifies a dedicated effort to push the boundaries of cancer treatment. The company continues to transform scientific discovery into practical health solutions, maintaining an evergreen role in the complex landscape of biopharmaceutical innovation.
Exelixis (EXEL) and Merck (MRK) have announced a clinical development collaboration to evaluate combinations of Exelixis' investigational tyrosine kinase inhibitor zanzalintinib with Merck's therapies in head and neck cancer and renal cell carcinoma (RCC). The collaboration includes:
1. A phase 3 trial combining zanzalintinib with KEYTRUDA (pembrolizumab) for head and neck squamous cell carcinoma (HNSCC).
2. A phase 1/2 trial and two phase 3 trials combining zanzalintinib with WELIREG (belzutifan) for RCC.
Merck will supply KEYTRUDA for the ongoing STELLAR-305 trial in HNSCC and sponsor the RCC trials. Exelixis will co-fund some studies and supply zanzalintinib and cabozantinib. Exelixis retains global commercial rights to zanzalintinib.
Exelixis (EXEL) announced final results from the phase 3 CABINET study evaluating cabozantinib in advanced neuroendocrine tumors (NET). The study showed significant improvement in progression-free survival (PFS) versus placebo in both pancreatic NET (pNET) and extra-pancreatic NET (epNET) cohorts:
- pNET cohort: median PFS of 13.8 months for cabozantinib vs 4.4 months for placebo (HR 0.23, p<0.0001)
- epNET cohort: median PFS of 8.4 months vs 3.9 months (HR 0.38, p<0.0001)
The data supported Exelixis' supplemental New Drug Application to the FDA for cabozantinib in advanced NET, with a target action date of April 3, 2025. The safety profile was consistent with known data, and no new signals were identified.
Exelixis (EXEL) presented final overall survival (OS) results from the CONTACT-02 phase 3 study evaluating cabozantinib (CABOMETYX®) with atezolizumab in metastatic castration-resistant prostate cancer (mCRPC) at ESMO 2024. The study showed a numerical but not statistically significant improvement in OS favoring the combination (HR: 0.89; P=0.296). Notably, improved OS was observed in patients with bone or liver metastases. The combination demonstrated a manageable safety profile with treatment-related grade 3-4 adverse events occurring in 40% of patients. Exelixis plans to submit a supplemental New Drug Application for this combination in mCRPC later this year, based on the previously reported statistically significant progression-free survival benefit.
Exelixis (Nasdaq: EXEL) has announced its participation in three major investor conferences this September. The company will present at:
- Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 at 9:15 a.m. ET in New York City
- 2024 Wells Fargo Healthcare Conference on September 6 at 10:15 a.m. ET in Everett, MA
- Bank of America Global Healthcare Conference 2024 on September 18 at 10:50 a.m. BST in London, UK
All presentations will be webcast live on www.exelixis.com under the Investors & News section. Replays will be available for at least 30 days after each event.
Exelixis (NASDAQ: EXEL) has initiated the dose-escalation stage of the first-in-human phase 1 clinical trial of XB010 in patients with locally advanced or metastatic solid tumors. XB010 is an antibody-drug conjugate (ADC) targeting the tumor antigen 5T4, developed through Exelixis' biotherapeutics collaboration network. The trial will evaluate XB010 as a single agent and in combination with pembrolizumab. The study includes a dose-escalation stage followed by expansion cohorts to assess tolerability and activity in specific indications. XB010 was constructed using Catalent's SMARTag site-specific bioconjugation platform, with its 5T4-targeting mAb discovered in collaboration with Invenra.
Exelixis (Nasdaq: EXEL) announced its Q2 2024 financial results, reporting total revenues of $637.2 million, up from $469.8 million in Q2 2023. Net product revenues from the cabozantinib franchise reached $437.6 million, with a GAAP diluted EPS of $0.77 and non-GAAP diluted EPS of $0.84.
The FDA accepted a supplemental new drug application (sNDA) for cabozantinib in advanced neuroendocrine tumors (NET), targeting a review date of April 3, 2025. Exelixis also announced a $150 million milestone payment from Ipsen and completed a $450 million stock repurchase program. An additional $500 million stock repurchase program is planned through the end of 2025.
Operating expenses showed a decrease in R&D and SG&A, leading to a GAAP net income of $226.1 million compared to $81.2 million in Q2 2023. Exelixis also highlighted updated clinical developments including the completion of the phase 3 CONTACT-02 study in metastatic castration-resistant prostate cancer.
Exelixis (Nasdaq: EXEL) announced that the FDA has accepted its supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for treating advanced neuroendocrine tumors (NET). The application covers two indications: previously treated pancreatic NET (pNET) and extra-pancreatic NET (epNET). The FDA granted orphan drug designation for pNET and set a target action date of April 3, 2025.
The sNDA is based on the phase 3 CABINET trial results, which showed statistically significant and clinically meaningful improvement in progression-free survival with cabozantinib versus placebo. The trial was stopped early due to compelling activity, allowing placebo patients to cross over to cabozantinib. Final results will be presented at the 2024 ESMO Congress in September.
Exelixis (Nasdaq: EXEL) has announced the release date for its second quarter 2024 financial results. The company will disclose its financial performance on Tuesday, August 6, 2024, after the markets close. Following the release, Exelixis management will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a general business update.
Interested parties can access the event through the company's website. To join the conference call, registration is required via a provided link, which will furnish a dial-in number and unique PIN. The live webcast can be accessed through the Event Calendar page under the Investors & News section of www.exelixis.com. A replay of the webcast will be available on the company's website for one year.
Exelixis (Nasdaq: EXEL) announced its participation in the William Blair 44th Annual Growth Stock Conference. The company will present a fireside chat on June 4 at 4:20 p.m. ET in Chicago.
The event will be webcast live on the company’s website, www.exelixis.com, and a replay will be available for at least 30 days post-event.
Exelixis (Nasdaq: EXEL) announced a settlement with Cipla and Cipla USA, Inc. regarding two patent litigations over CABOMETYX® (cabozantinib) tablets. The disputes stemmed from Cipla's ANDA seeking approval to market generic versions of CABOMETYX before the expiration of Exelixis' patents. The first litigation, filed on March 16, 2023, concerned a 60 mg dosage, and the second, filed on May 9, 2024, involved 20 mg and 40 mg dosages. Under the settlement, Cipla will be licensed to market generic CABOMETYX in the US from January 1, 2031, conditional on FDA approval. All ongoing litigation will be terminated, subject to FTC and DOJ review. The agreement details remain confidential.